Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

New data for KidneyIntelX

June 28, 2021
RNS Number : 2844D Renalytix PLC 28 June 2021   Renalytix plc   (" Renalytix " or the " Company ")     KidneyIntelX TM Enables Monitoring of SGLT2 Inhibitor Therapy Response and Corresponding Risk Reduction Over Time   Study Results lay foundation for KidneyIntelX repeat testing, reimbursement, and

Director/PDMR Dealing

June 25, 2021
RNS Number : 2249D Renalytix PLC 25 June 2021     Renalytix plc    ("Renalytix" or the "Company")   Director/PDMR Dealing   The Company was informed that today, Fergus Fleming , Chief Technology Officer, completed the sale of 15,000 ordinary shares of 0.25 pence each ("Ordinary Shares") in the

Exercise of options

June 25, 2021
RNS Number : 1945D Renalytix PLC 25 June 2021   Renalytix plc   (" Renalytix " or the " Company ")     Exercise of options and total voting rights   NEW YORK , June 25, 2021 - Renalytix plc (LSE: RENX) (NASDAQ: RNLX) announces that it has issued and allotted 150,000 ordinary shares of 0.25 pence

Change of name

June 24, 2021
RNS Number : 0409D Renalytix AI PLC 24 June 2021   Renalytix AI plc   (" Renalytix " or the " Company ")     Change of name to Renalytix Plc Change of registered office Change of website   NEW YORK , June 24, 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announces it has changed its name to

Director/PDMR Shareholding - Replacement

June 22, 2021
RNS Number : 7366C Renalytix AI PLC 22 June 2021   The following amendment(s) has been made to the ' Director/PDMR Dealing ' announcement released on 22 June 2021 at 10:57 under RNS No 7062C.   The price of 113.5 pence per share was incorrect and has been amended to 1135 pence per share.

Director/PDMR Shareholding

June 22, 2021
RNS Number : 7062C Renalytix AI PLC 22 June 2021   Renalytix AI plc    ("Renalytix" or the "Company") Director/PDMR Dealing The Company was informed that today, Christopher Mills , a non-executive director and interim Chairman, completed the sale of 17,000 ordinary shares of 0.25 pence each

Financial Results for Third Quarter of FY 2021

June 15, 2021
RNS Number : 9139B Renalytix AI PLC 15 June 2021   Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2021   NEW YORK , June 15, 2021   - Renalytix AI plc   (LSE : RENX) (NASDAQ: RNLX) ("Renalytix" or the "Company") today reported financial results for the quarter and nine months

Notice of Results & Change of Auditor

June 10, 2021
RNS Number : 4033B Renalytix AI PLC 10 June 2021   Renalytix AI plc (" Renalytix " or the " Company ")   Renalytix to Report Financial Results for Fiscal Third Quarter 2021 and Provide Corporate Update   Announces Change of Auditor to Ernst & Young LLP   NEW YORK ,  June 10, 2021   - Renalytix AI

Key new hires to drive commercialization strategy

June 7, 2021
RNS Number : 9511A Renalytix AI PLC 07 June 2021     Renalytix AI plc (" Renalytix " or the " Company ")   Leadership additions announced to support expanding US Government and Healthcare Provider KidneyIntelX Deployment   Enabling expertise in sales, population health and value-driven care models

Utility Study

June 3, 2021
RNS Number : 6483A Renalytix AI PLC 03 June 2021   Renalytix AI plc   (" Renalytix " or the " Company ")     Utility Study Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care   Clinicians affirm need for accurate early-stage diabetic kidney disease risk assessment
Displaying 71 - 80 of 209